Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction

Hypertension

Volumn 45, Issue 1, 2005, Pages 120-125

  Van Esch, Joep H M ^a   Tom, Beril ^a   Dive, Vincent ^b   Batenburg, Wendy W ^a   Georgiadis, Dimitris ^c   Yiotakis, Athanasios ^c   Van Gool, Jeanette M G ^a   De Bruijn, René J A ^a   De Vries, René ^a   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CEA SACLAY   (France)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiotensin; Angiotensin converting enzyme; Bradykinin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE; QUINAPRILAT; RXP 407; RXPA 380; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD PRESSURE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; ENZYME INHIBITION; FEMALE; FEMORAL ARTERY; HALF LIFE TIME; HORMONE METABOLISM; HUMAN; HUMAN TISSUE; HYDROLYSIS; HYPERTENSION; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; SWINE; VASOCONSTRICTION; VASODILATATION;

ADOLESCENT; ADULT; ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CAPTOPRIL; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL ARTERY; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; OLIGOPEPTIDES; ORGAN SPECIFICITY; PEPTIDYL-DIPEPTIDASE A; PHOSPHINIC ACIDS; PROTEIN STRUCTURE, TERTIARY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUS SCROFA; TETRAHYDROISOQUINOLINES; VASOCONSTRICTION;

EID: 19944427503     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000151323.93372.f5     Document Type: Article

References (26)

1. Tom B, de Vries R, Saxena PR, Danser AHJ. Bradykinin potentiation by angiotensin-(1-7) and angiotensin-converting enzyme (ACE) inhibitors correlates with ACE C- and N-domain blockade. Hypertension. 2001;38:95-99.
2. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003;93:148-154.
3. Junot C, Gonzales MF, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, Dive V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001;297:606-611.
4. Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, Zhao H, Keshelava G, Capecchi MR, Corvol P, Bernstein KE. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem. 2004;279:15946-15953.
5. Perich RB, Jackson B, Johnston CI. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol. 1994;266:201-211.
6. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
7. Michaud A, Williams TA, Chauvet MT, Corvol P. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol. 1997;51:1070-1076.
8. Schuijt MP, de Vries R, Saxena PR, Schalekamp MADH, Danser AHJ. Vasoconstriction is determined by interstitial rather than circulating angiotensin II. Br J Pharmacol. 2002;135:275-283.
9. Danser AHJ, Chowdury S, de Lannoy LM, van der Giessen WJ, Saxena PR, Schalekamp MADH. Conversion and degradation of [125I] labeled angiotensin I in isolated perfused porcine coronary and carotid arteries. Cardiovasc Res. 1995;29:789-795.
10. Tom B, Dendorfer A, de Vries R, Saxena PR, Danser AHJ. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol. 2002;137:276-284.
11. Santos RAS, Simoes e Silva AC, Marie C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.
12. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MADH, Danser AHJ. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res. 1999;44:407-415.
13. Tom B, Garrelds IM, Scalbert E, Stegmann APA, Boomsma F, Saxena PR, Danser AHJ. ACE- versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency? Arterioscler Thromb Vasc Biol. 2003;23:251-256.
14. Admiraal PJJ, Danser AHJ, Jong MS, Pieterman H, Derkx FHM, Schalekamp MADH. Regional angiotensin II production in essential hypertension and renal artery stenosis. Hypertension. 1993;21:173-184.
15. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19-26.
16. Batenburg WW, Garrelds IM, van Kats JP, Saxena PR, Danser AHJ. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension. 2004;43:488-492.
17. van Kesteren CAM, Saris JJ, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II. Cardiovasc Res. 1999;43:148-156.
18. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802.
19. Roks AJM, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension. 1999;34:296-301.
20. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, Umemura S, Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension. 2000;35:998-1001.
21. Danser AHJ, Admiraal PJJ, Derkx FHM, Schalekamp MADH. Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens. 1998;16:2051-2056.
22. Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res. 2004;94:60-67.
23. Danser AHJ, Koning MMG, Admiraal PJJ, Sassen LMA, Derkx FHM, Verdouw PD, Schalekamp MADH. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992;263:H429-H437.
24. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992;107:970-975.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
26. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550.